Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00099723
Status:
TERMINATED
Last Update Posted:
2010-02-11
First Post:
2004-12-17
Brief Title:
The Effect of a Probiotic on Hepatic Steatosis
Sponsor:
VSL Pharmaceuticals
Organization:
VSL Pharmaceuticals
Study Overview
Official Title:
The Effect of a Probiotic on Hepatic Steatosis
Status:
TERMINATED
Status Verified Date:
2004-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The hypothesis that probiotics would reduce hepatic steatosis in humans was not supported
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Non-alcoholic fatty liver disease NAFLD is an accumulation of fat and fibrous tissue in the liver It is the most common cause of chronic liver disease in the United States The exact cause of NAFLD is unknown but it is more common among people with conditions such as adult-onset diabetes NAFLD can strike people of all ages but most often affects adults between the ages of 40 and 60 Research indicates that overgrowth of gut bacteria can start a chain of biological processes that stress the liver causing liver inflammation Probiotics living bacteria taken orally may decrease the stress on the liver by reducing this bacterial overgrowth andor strengthening the gut walls Because probiotics are generally safe inexpensive and easy to tolerate they are an attractive treatment option for NAFLD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R21AT001305-01 | NIH | None | httpsreporternihgovquickSearchR21AT001305-01 |